Integra LifeSciences (IART) Stock Forecast, Price Target & Predictions
IART Stock Forecast
Integra LifeSciences stock forecast is as follows: an average price target of $43.25 (represents a 147.57% upside from IART’s last price of $17.47) and a rating consensus of 'Sell', based on 6 wall street analysts offering a 1-year stock forecast.
IART Price Target
The average price target for Integra LifeSciences (IART) is $43.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $22.00. This represents a potential 147.57% upside from IART's last price of $17.47.
IART Analyst Ratings
According to 6 Wall Street analysts, Integra LifeSciences's rating consensus is 'Sell'. The analyst rating breakdown for IART stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 1 'Hold' (16.67%), 3 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Integra LifeSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Richard Newitter | Truist Financial | $26.00 | $24.59 | 5.73% | 48.83% |
| Jul 30, 2024 | Joanne Wuensch | Citigroup | $23.00 | $25.42 | -9.52% | 31.65% |
| Jul 29, 2024 | Ryan Zimmerman | BTIG | $22.00 | $25.42 | -13.45% | 25.93% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $32.00 | $29.84 | 7.24% | 83.17% |
| May 07, 2024 | Richard Newitter | Truist Financial | $25.00 | $23.14 | 8.04% | 43.10% |
| May 07, 2024 | David Turkaly | JMP Securities | $40.00 | $23.14 | 72.86% | 128.96% |
| May 06, 2024 | Vik Chopra | Wells Fargo | $25.00 | $23.14 | 8.04% | 43.10% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | $50.00 | $46.85 | 6.72% | 186.20% |
| Jul 28, 2022 | FY22 EPS | Piper Sandler | $55.00 | $56.53 | -2.71% | 214.83% |
| May 20, 2021 | Anthony Petrone | Jefferies | $86.00 | $70.95 | 21.21% | 392.27% |
The latest Integra LifeSciences stock forecast, released on Jul 30, 2024 by Richard Newitter from Truist Financial, set a price target of $26.00, which represents a 5.73% increase from the stock price at the time of the forecast ($24.59), and a 48.83% increase from IART last price ($17.47).
Integra LifeSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 7 |
| Avg Price Target | - | $25.75 | $27.57 |
| Last Closing Price | $17.47 | $17.47 | $17.47 |
| Upside/Downside | -100.00% | 47.40% | 57.81% |
In the current month, the average price target of Integra LifeSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Integra LifeSciences's last price of $17.47. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 30, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jul 30, 2024 | Citigroup | Neutral | Sell | Downgrade |
| Jul 29, 2024 | BTIG | Sell | Negative | Downgrade |
| Jul 29, 2024 | BTIG | - | Sell | Downgrade |
| Jul 15, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 10, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 22, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 07, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| May 07, 2024 | Truist Financial | Underperform | Underperform | Hold |
| May 07, 2024 | JMP Securities | Outperform | Outperform | Hold |
Integra LifeSciences's last stock rating was published by JMP Securities on Jul 30, 2024. The company gave IART a "Market Outperform" rating, the same as its previous rate.
Integra LifeSciences Financial Forecast
Integra LifeSciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $381.27M | $380.85M | $398.02M | $385.19M | $397.81M | $376.64M | $405.52M | $386.86M | $389.99M | $360.07M | $388.65M | $370.23M | $258.67M | $354.32M | $395.13M | $379.10M | $383.64M | $359.69M | $357.08M | $258.64M |
| Avg Forecast | $457.31M | $412.64M | $431.36M | $409.17M | $449.18M | $375.80M | $413.07M | $363.74M | $399.34M | $387.22M | $374.01M | $373.23M | $397.92M | $378.33M | $395.35M | $362.41M | $404.56M | $384.62M | $376.11M | $349.78M | $389.06M | $351.65M | $243.82M | $359.84M | $397.52M | $376.27M | $373.29M | $360.38M | $301.69M | $251.97M |
| High Forecast | $461.18M | $416.14M | $435.01M | $412.63M | $452.98M | $378.67M | $416.56M | $366.82M | $400.71M | $390.50M | $377.18M | $376.39M | $401.29M | $381.53M | $398.53M | $365.33M | $407.81M | $387.72M | $379.14M | $352.60M | $392.19M | $354.48M | $245.78M | $362.74M | $400.72M | $379.30M | $376.29M | $363.28M | $362.03M | $302.36M |
| Low Forecast | $454.17M | $409.81M | $428.40M | $406.36M | $446.09M | $373.68M | $410.23M | $361.25M | $397.66M | $384.56M | $371.44M | $370.67M | $395.19M | $375.73M | $392.87M | $360.14M | $402.02M | $382.21M | $373.75M | $347.59M | $386.62M | $349.45M | $242.29M | $357.59M | $395.03M | $373.92M | $370.95M | $358.12M | $241.35M | $201.58M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.00% | 1.02% | 1.01% | 1.04% | 1.00% | 1.01% | 1.04% | 1.03% | 1.00% | 1.05% | 1.06% | 0.98% | 0.99% | 1.01% | 1.03% | 1.00% | 1.18% | 1.03% |
Integra LifeSciences's average Quarter revenue forecast for Sep 23 based on 4 analysts is $387.22M, with a low forecast of $384.56M, and a high forecast of $390.50M. IART's average Quarter revenue forecast represents a 1.56% increase compared to the company's last Quarter revenue of $381.27M (Jun 23).
Integra LifeSciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $12.50M | $44.99M | $80.64M | $100.43M | $93.42M | $80.69M | $67.99M | $93.10M | $87.73M | $109.42M | $82.44M | $93.33M | $47.01M | $58.34M | $67.75M | $14.05M | $76.66M | $65.06M | $55.00M | $29.59M |
| Avg Forecast | $73.42M | $66.25M | $69.25M | $65.69M | $72.11M | $60.33M | $66.32M | $89.02M | $64.11M | $62.17M | $60.05M | $80.93M | $63.89M | $82.50M | $63.47M | $73.57M | $64.95M | $61.75M | $60.38M | $86.39M | $62.46M | $56.46M | $39.14M | $72.24M | $63.82M | $60.41M | $59.93M | $60.80M | $44.89M | $28.81M |
| High Forecast | $74.04M | $66.81M | $69.84M | $66.25M | $72.72M | $60.80M | $66.88M | $106.83M | $64.33M | $62.69M | $60.56M | $97.12M | $64.43M | $99.00M | $63.98M | $88.29M | $65.47M | $62.25M | $60.87M | $103.66M | $62.97M | $56.91M | $39.46M | $86.68M | $64.33M | $60.90M | $60.41M | $72.96M | $53.87M | $34.58M |
| Low Forecast | $72.92M | $65.79M | $68.78M | $65.24M | $71.62M | $59.99M | $65.86M | $71.22M | $63.84M | $61.74M | $59.63M | $64.75M | $63.45M | $66.00M | $63.07M | $58.86M | $64.54M | $61.36M | $60.01M | $69.11M | $62.07M | $56.10M | $38.90M | $57.79M | $63.42M | $60.03M | $59.56M | $48.64M | $35.92M | $23.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.21% | 0.56% | 1.26% | 1.22% | 1.47% | 1.10% | 1.05% | 1.51% | 1.45% | 1.27% | 1.32% | 1.65% | 1.20% | 0.81% | 1.06% | 0.23% | 1.28% | 1.07% | 1.23% | 1.03% |
4 analysts predict IART's average Quarter EBITDA for Sep 23 to be $62.17M, with a high of $62.69M and a low of $61.74M. This is 397.18% upper than Integra LifeSciences's previous annual EBITDA (Jun 23) of $12.50M.
Integra LifeSciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $4.18M | $24.23M | $52.95M | $49.91M | $44.79M | $32.90M | $45.38M | $43.23M | $35.07M | $45.39M | $92.74M | $32.34M | $-369.00K | $9.18M | $15.32M | $-27.61M | $29.74M | $32.76M | $10.99M | $6.39M |
| Avg Forecast | $61.61M | $46.70M | $45.20M | $42.65M | $67.77M | $30.21M | $48.26M | $36.30M | $69.90M | $60.25M | $44.07M | $33.00M | $69.95M | $38.31M | $61.87M | $30.00M | $65.08M | $56.08M | $50.99M | $35.84M | $56.73M | $42.01M | $6.95M | $11.37M | $51.67M | $50.65M | $50.73M | $30.61M | $8.97M | $6.23M |
| High Forecast | $62.28M | $47.21M | $45.70M | $43.12M | $68.51M | $32.54M | $48.79M | $43.56M | $70.67M | $60.91M | $44.55M | $39.60M | $70.72M | $45.97M | $62.52M | $36.00M | $65.76M | $56.66M | $51.52M | $43.00M | $57.32M | $42.45M | $7.02M | $13.64M | $52.21M | $51.18M | $51.26M | $36.73M | $10.77M | $7.47M |
| Low Forecast | $61.06M | $46.28M | $44.80M | $42.27M | $67.16M | $28.66M | $47.83M | $29.04M | $69.12M | $59.71M | $43.67M | $26.40M | $69.32M | $30.64M | $61.37M | $24.00M | $64.55M | $55.62M | $50.57M | $28.67M | $56.27M | $41.67M | $6.89M | $9.09M | $51.25M | $50.24M | $50.32M | $24.49M | $7.18M | $4.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.09% | 0.73% | 0.76% | 1.30% | 0.72% | 1.10% | 0.70% | 0.77% | 0.69% | 1.27% | 1.63% | 0.77% | -0.05% | 0.81% | 0.30% | -0.55% | 0.59% | 1.07% | 1.23% | 1.03% |
Integra LifeSciences's average Quarter net income forecast for Sep 23 is $60.25M, with a range of $59.71M to $60.91M. IART's average Quarter net income forecast represents a 1340.06% increase compared to the company's last Quarter net income of $4.18M (Jun 23).
Integra LifeSciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $164.91M | $166.66M | $151.92M | $143.82M | $160.65M | $159.93M | $162.25M | $156.01M | $162.55M | $156.63M | $162.39M | $150.08M | $116.11M | $165.95M | $174.25M | $173.10M | $165.38M | $174.87M | $163.57M | $142.50M |
| Avg Forecast | $191.35M | $172.66M | $180.49M | $171.21M | $187.95M | $157.25M | $172.84M | $176.44M | $167.09M | $162.02M | $156.50M | $160.40M | $166.50M | $138.24M | $165.42M | $145.81M | $169.28M | $160.94M | $157.37M | $123.66M | $162.79M | $147.14M | $102.02M | $205.46M | $166.33M | $157.44M | $156.19M | $163.40M | $133.52M | $138.75M |
| High Forecast | $192.97M | $174.12M | $182.02M | $172.66M | $189.54M | $158.45M | $174.30M | $211.72M | $167.67M | $163.39M | $157.82M | $192.48M | $167.91M | $165.89M | $166.75M | $174.98M | $170.64M | $162.23M | $158.64M | $148.39M | $164.10M | $148.32M | $102.84M | $246.56M | $167.67M | $158.71M | $157.45M | $196.08M | $160.23M | $166.50M |
| Low Forecast | $190.04M | $171.48M | $179.25M | $170.03M | $186.66M | $156.36M | $171.65M | $141.15M | $166.39M | $160.91M | $155.42M | $128.32M | $165.36M | $110.59M | $164.39M | $116.65M | $168.22M | $159.93M | $156.39M | $98.93M | $161.77M | $146.22M | $101.38M | $164.37M | $165.29M | $156.46M | $155.21M | $130.72M | $106.82M | $111.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | 0.91% | 1.04% | 0.97% | 1.10% | 0.96% | 0.97% | 1.03% | 1.27% | 1.00% | 1.02% | 1.14% | 0.81% | 1.05% | 1.10% | 1.06% | 1.07% | 1.23% | 1.03% |
Integra LifeSciences's average Quarter SG&A projection for Sep 23 is $162.02M, based on 4 Wall Street analysts, with a range of $160.91M to $163.39M. The forecast indicates a -1.75% fall compared to IART last annual SG&A of $164.91M (Jun 23).
Integra LifeSciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.05 | $0.30 | $0.63 | $0.60 | $0.54 | $0.39 | $0.54 | $0.51 | $0.41 | $0.54 | $1.10 | $0.38 | $-0.00 | $0.11 | $0.18 | $-0.32 | $0.35 | $0.38 | $0.14 | $0.09 |
| Avg Forecast | $0.80 | $0.60 | $0.58 | $0.55 | $0.88 | $0.39 | $0.62 | $0.55 | $0.90 | $0.78 | $0.57 | $0.74 | $0.90 | $0.72 | $0.80 | $0.68 | $0.84 | $0.72 | $0.66 | $0.57 | $0.73 | $0.54 | $0.09 | $0.62 | $0.67 | $0.65 | $0.66 | $0.61 | $0.40 | $0.37 |
| High Forecast | $0.80 | $0.61 | $0.59 | $0.56 | $0.89 | $0.42 | $0.63 | $0.56 | $0.91 | $0.79 | $0.58 | $0.75 | $0.91 | $0.73 | $0.81 | $0.69 | $0.85 | $0.73 | $0.67 | $0.57 | $0.74 | $0.55 | $0.09 | $0.63 | $0.67 | $0.66 | $0.66 | $0.61 | $0.48 | $0.44 |
| Low Forecast | $0.79 | $0.60 | $0.58 | $0.55 | $0.87 | $0.37 | $0.62 | $0.55 | $0.89 | $0.77 | $0.56 | $0.73 | $0.90 | $0.71 | $0.79 | $0.68 | $0.83 | $0.72 | $0.65 | $0.56 | $0.73 | $0.54 | $0.09 | $0.62 | $0.66 | $0.65 | $0.65 | $0.60 | $0.32 | $0.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.09% | 0.41% | 0.70% | 0.83% | 0.68% | 0.57% | 0.64% | 0.70% | 0.63% | 0.95% | 1.50% | 0.71% | -0.05% | 0.18% | 0.27% | -0.49% | 0.53% | 0.63% | 0.35% | 0.24% |
According to 4 Wall Street analysts, Integra LifeSciences's projected average Quarter EPS for Sep 23 is $0.78, with a low estimate of $0.77 and a high estimate of $0.79. This represents a 1405.53% increase compared to IART previous annual EPS of $0.05 (Jun 23).
Integra LifeSciences Peer Comparison by Price Target
IART Forecast FAQ
Is Integra LifeSciences a good buy?
No, according to 6 Wall Street analysts, Integra LifeSciences (IART) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of IART's total ratings.
What is IART's price target?
Integra LifeSciences (IART) average price target is $43.25 with a range of $22 to $86, implying a 147.57% from its last price of $17.47. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Integra LifeSciences stock go up soon?
According to Wall Street analysts' prediction for IART stock, the company can go up by 147.57% (from the last price of $17.47 to the average price target of $43.25), up by 392.27% based on the highest stock price target, and up by 25.93% based on the lowest stock price target.
Can Integra LifeSciences stock reach $30?
IART's average twelve months analyst stock price target of $43.25 supports the claim that Integra LifeSciences can reach $30 in the near future.
What are Integra LifeSciences's analysts' financial forecasts?
Integra LifeSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.6B (high $1.62B, low $1.59B), average EBITDA is $287.79M (high $307.23M, low $268.69M), average net income is $182.54M (high $193.4M, low $172.7M), average SG&A $694.47M (high $734.01M, low $655.81M), and average EPS is $2.44 (high $2.49, low $2.4). IART's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.71B (high $1.72B, low $1.7B), average EBITDA is $274.62M (high $276.94M, low $272.73M), average net income is $196.16M (high $198.32M, low $194.41M), average SG&A $715.71M (high $721.77M, low $710.8M), and average EPS is $2.53 (high $2.56, low $2.51).
Did the IART's actual financial results beat the analysts' financial forecasts?
Based on Integra LifeSciences's last annual report (Dec 2022), the company's revenue was $1.56B, beating the average analysts forecast of $1.53B by 1.54%. Apple's EBITDA was $276.73M, missing the average prediction of $283.43M by -2.37%. The company's net income was $180.55M, missing the average estimation of $200.12M by -9.78%. Apple's SG&A was $616.32M, beating the average forecast of $615.98M by 0.05%. Lastly, the company's EPS was $2.18, missing the average prediction of $3.11 by -29.82%. In terms of the last quarterly report (Jun 2023), Integra LifeSciences's revenue was $381.27M, beating the average analysts' forecast of $374.01M by 1.94%. The company's EBITDA was $12.5M, missing the average prediction of $60.05M by -79.18%. Integra LifeSciences's net income was $4.18M, missing the average estimation of $44.07M by -90.51%. The company's SG&A was $164.91M, beating the average forecast of $156.5M by 5.37%. Lastly, the company's EPS was $0.0517, missing the average prediction of $0.569 by -90.92%